Geoffrey Chupp, MD

Geoffrey Chupp, MD, is a pulmonologist who specializes in lung diseases that affect the airway, including severe asthma, Chronic Obstructive Pulmonary Disease (COPD), bronchiolitis, autoimmune airway diseases, and airway diseases that have not been classified.

Articles by Geoffrey Chupp, MD

Choosing an IL-5 Inhibitor for Asthma: Evidence, Comorbidities, Convenience

ByDavid Bernstein, MD ,Geoffrey Chupp, MD,Michael Wechsler, MD, MMSc ,Giselle Mosnaim, MD, MS

November 10th 2026

Selecting an IL-5 inhibitor begins with evidence and comorbidities, yet dosing schedule and site of care often determine whether patients can remain on therapy.

Payer Coverage and Authorization for Severe Asthma Biologics

ByDavid Bernstein, MD ,Geoffrey Chupp, MD,Michael Wechsler, MD, MMSc ,Giselle Mosnaim, MD, MS

November 10th 2026

Payer acceptance of asthma biologics has improved considerably, yet coverage still varies widely by health system, and plans can override a treatment choice reached through shared decision-making.

Addressing Patient Hesitancy Toward Biologic Therapy for Severe Asthma

ByDavid Bernstein, MD ,Geoffrey Chupp, MD,Michael Wechsler, MD, MMSc ,Giselle Mosnaim, MD, MS

November 3rd 2026

Reluctance toward injectable therapy is diminishing, but it persists. Dosing convenience and an honest conversation about the cumulative harm of steroid bursts can change a patient's decision.

Early Biologic Therapy in Asthma to Prevent Lung Function Decline

ByDavid Bernstein, MD ,Geoffrey Chupp, MD,Michael Wechsler, MD, MMSc ,Giselle Mosnaim, MD, MS

November 3rd 2026

Each exacerbation erodes lung function, and reduced lung function invites the next exacerbation. The panel explains why biologics are shifting from last resort to earlier intervention.

FDA-Approved Asthma Biologics: Mechanisms of Action and Treatment Selection

ByDavid Bernstein, MD ,Geoffrey Chupp, MD,Michael Wechsler, MD, MMSc ,Giselle Mosnaim, MD, MS

October 27th 2026

Seven approved biologics now target distinct points in the inflammatory cascade, giving clinicians genuine options, even for patients with low eosinophil levels.

Biologic Dosing Frequency and Real-World Persistence in Severe Asthma

ByDavid Bernstein, MD ,Geoffrey Chupp, MD,Michael Wechsler, MD, MMSc ,Giselle Mosnaim, MD, MS

October 27th 2026

Every dose is another opportunity to miss one. Real-world evidence indicates that longer biologic dosing intervals are associated with higher persistence and fewer treatment gaps.

Optimizing Asthma Adherence: Inhaler Technique, Cost, and Team-Based Care

ByDavid Bernstein, MD ,Geoffrey Chupp, MD,Michael Wechsler, MD, MMSc ,Giselle Mosnaim, MD, MS

October 20th 2026

Adherence depends on clear explanation, reliable inhaler technique, and affordable medication, and gaps in any one of these can quietly erode the benefit of an effective treatment plan.

Setting Realistic Asthma Treatment Goals Across Diverse Patient Populations

ByDavid Bernstein, MD ,Geoffrey Chupp, MD,Michael Wechsler, MD, MMSc ,Giselle Mosnaim, MD, MS

October 20th 2026

Whether the goal is remission or simply fewer exacerbations depends heavily on the population served, and repeated steroid bursts quickly accumulate into lasting harm.

Asthma Remission Goals and Where Biologic Adherence Breaks Down

ByDavid Bernstein, MD ,Geoffrey Chupp, MD,Michael Wechsler, MD, MMSc ,Giselle Mosnaim, MD, MS

October 13th 2026

Current biologics halve exacerbations but achieve remission in a minority of patients, and adherence often falters before therapy begins or around the 6-month mark.

Biologic Value in Asthma: Oral Steroid Toxicity and Prior Authorization

ByDavid Bernstein, MD ,Geoffrey Chupp, MD,Michael Wechsler, MD, MMSc ,Giselle Mosnaim, MD, MS

October 13th 2026

Biologics can offset their acquisition cost by preventing exacerbations and cumulative steroid toxicity, yet billing structures and prior authorization continue to delay patients who need treatment.

Severe Asthma Exacerbations, Indirect Costs, and When to Escalate Therapy

ByDavid Bernstein, MD ,Geoffrey Chupp, MD,Michael Wechsler, MD, MMSc ,Giselle Mosnaim, MD, MS

October 6th 2026

Asthma costs extend well beyond the emergency department, into lost schooling, reduced earning potential, and steroid harm, which sharpens the case for recognizing uncontrolled disease and escalating care promptly.